Validated UV-Vis spectrophotometric method for the estimation of Sorafenib Tosylate in bulk and nanoparticles
Keywords:
sorafenib, ultraviolet visible, bulk, nanoparticlesAbstract
It was noticed from the standard databases such as Scopus, PubMed, ScienceDirect, etc. that a limited UV-Vis spectrophotometric method has been reported for estimating Sorafenib (SOR), but no sophisticated analytical methods have been ever reported in any database for estimating SOR in nanoparticles. The present research involved the establishment of an economic, accurate, robust, and precise analytical method for the quantitative determination of SOR in bulk and nanoparticles utilizing a new validated spectrophotometric method. The spectrophotometric analysis was carried out using double-beam ultraviolet-visible spectrophotometer was employed in developing a new method using methanol and water at a ratio of 80:20 v/v and λmax of 265 nm. The technique was verified using the Q2A and Q2B guidelines of ICH. The newly developed UV-Vis method had desired linearity over the range of 2-12 μg/mL; along with excellent precision, accuracy, ruggedness, and robustness characteristics as observed from % RSD values of less than 2. The present study concluded that the developed UV-Vis method has desired linearity, precision, accuracy, ruggedness, and robustness, and will serve as an excellent technique for the determination of sorafenib in both bulk and nanoparticles without the interference of commonly used chemicals or solvents.
Downloads
References
Grochulski, P., Masson, L., Borisova, S., Pusztai, M.C., Schwarta, J.L., Brousseau R. & Cygler, M. (1995). Bacillus thuringiensis Cry1A (a) insecticidal toxin: Crystal structure and channel formation. J. Mol. Biol., 254(2):447-464.
Iyer R., Fetterly G., Lugade A., Thanavala Y.[2010]. Sorafenib: a clinical and pharmacologic review. Exp Opin Pharmacother. 11(11):1943-55.
Bronte G., Andreis D., Bravaccini S., Maltoni R., Cecconetto L., Schirone A., Farolfi A., Fedeli A., Serra P., Donati C., Amadori D.[ 2017] Sorafenib for the treatment of breast cancer. Exp Opin Pharmaco.,18(6):621-30.
Gradishar WJ.[ 2012]. Sorafenib in locally advanced or metastatic breast cancer. Exp Opin Investig Drug., 21(8):1177-91.
Moreno-Aspitia A.[ 2010]. Clinical overview of sorafenib in breast cancer. Future Oncol., 6(5):655-63.
Zafrakas M., Papasozomenou P., Emmanouilides C. [2016]. Sorafenib in breast cancer treatment: A systematic review and overview of clinical trials. World J Clin Oncol.,7(4):331.
Rini B.I.[2006]. Sorafenib.Expert Opin Pharmacother.,7(4):453-61.
Keating G.M., Santoro A. [2009] Sorafenib. Drugs.,69(2):223-40.
Hahn O., Stadler W. [2006]. Sorafenib. Curr Opin Oncol.,18(6):615-21.
VenkataRao S., Ramu G., Babu AB., Neeharika T., Rambabu C. [2011]. Determination of sorafenib in bulk and tablet formulation by a new validated reverse phase high performance liquid chromatography. Tablet.,100(99.48):99-148.
Zhao M., Rudek MA., He P., Hafner FT., Radtke M., Wright JJ., Smith BD., Messersmith WA., Hidalgo M., Baker SD.[ 2007]. A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. J Chromatograph B.,846(1-2):1-7.
Sun R., Hu C., Dou Q., Luan L.[ 2021]. Simultaneous Determination of Nine Residual Solvents in Sorafenib Tosylate by Gas Chromatography. J AOAC Int.,104(4):1005-9.
Sharma T., Khurana RK., Borges B., Kaur R., Katare OP., Singh B.[ 2021].An HPTLC densitometric method for simultaneous quantification of sorafenib tosylate and chrysin: Analytical method development, validation and applications. Microchemical J.,162:105821.
Ravisankar P., Babu PS., Taslim SM., Kamakshi K., Manasa RL.[ 2019]. Development and validation of UV-spectrophotometric method for determination of sorafenib in pharmaceutical dosage form and its degradation behaviour under various stress conditions. Int J Pharm Sci Rev Res.,56:12-17.
Deodhe S, Dhabarde DM, Kamble MA, Mahapatra DK.[2017].Novel stability indicating RP-HPLC method for the estimation of pinaverium bromide in tablet formulation: Assay development and validation. Eur J Anal Chem., 12(2):3-16.
Kanthale SB, Thonte SS, Pekamwar SS, Mahapatra DK.[2020].Development and Validation of a Stability Indicating RP-HPLC Method for the Determination of Prucalopride succinate in Bulk and Tablet. Int J Pharm Sci Drug Res.,12(2):166-74.
Sawale V., Dhabarde DM., Mahapatra DK.[2017]. Development and validation of UV spectrophotometric method for simultaneous estimation of olmesartan medoxomil and chlorthalidone in bulk and pharmaceutical dosage form. Eur J Anal Chem.,12(1):55-66.
Kanthale SB., Thonte SS., Mahapatra DK.[2019]. Development of Validated Stability Indicating RP-HPLC Method for the Estimation of Glecaprevir and Pibrentasvir in Bulk and Pharmaceutical Dosage Form. J Appl Pharm Sci.,9(6):52-60.
Deodhe S., Dhabarde DM., Kamble MA., Mahapatra DK.[ 2017].Development and validation of a novel stability indicating RP-HPLC method for the estimation of entecavir in tablet formulation. Eur J Anal Chem.12(3):223-35.
Puranik M., Shambharkar S., Nimbalkar S., Mahapatra DK.[2020].Comparison of UV Spectrophotometric and RP-HPLC Method for the Estimation of Deflazacort in Solid Dosage Form. J Appl Pharm Sci.,10(7):82-8.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
